
Proactive adverse event management for talazoparib plus enzalutamide in metastatic APMS. @CaPsurvivorship @DanaFarber joins @neerajaiims @huntsmancancer to discuss anemia management in the TALAPRO-3 regimen. The trial added talazoparib to enzalutamide in HRR-mutated metastatic hormone-sensitive prostate cancer, achieving 52% rPFS risk reduction. Dr. Morgans recommends an anemia panel at baseline to identify correctable causes before attributing low hemoglobin to treatment. #WatchNow > bit.ly/45AOzWS















